Rectum

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

Retrieved on: 
Vendredi, avril 26, 2024
University, CFO, Bangladesh Technical Education Board, Cancer, National Cancer Institute, FAP, Bladder cancer, Patient, Acquisition, Rectum, Moses Austin, Pharmaceutical industry

Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa’s oncology pipeline and adds numerous valuation catalysts for our stakeholders.

Key Points: 
  • Stephen Stamp, CEO and CFO of Biodexa said, “Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa’s oncology pipeline and adds numerous valuation catalysts for our stakeholders.
  • Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas.
  • We thank the scientists, clinicians, investors and biotech executives that supported our efforts to reach this important milestone.
  • We look forward to working with the Biodexa team as we embark upon this next chapter.”

Colorectal Cancer Screening and Diagnostics Industry Research 2024: Competitive Landscape, Pricing Analysis, Testing Volume, Analysis and Forecasts 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Mercredi, avril 10, 2024
Health, Oncology, Cancer, Colorectal cancer, Genomics, Investment, Danaher Corporation, Laboratory, Sigmoidoscopy, Hospital, Competitive landscape, Region, Insurance, Research, DNA, Helmy Eltoukhy, Incidence, Patient, Volume, Colonoscopy, Diagnosis, Rectum, Quality of life, Growth

The "Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type, End User, Region, and Competitive Landscape, Pricing Analysis, Testing Volume - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type, End User, Region, and Competitive Landscape, Pricing Analysis, Testing Volume - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global colorectal cancer screening and diagnostics market is projected to experience substantial growth over the forecast period 2023-2033.
  • Based on type, the colonoscopies and sigmoidoscopies segment dominated the global colorectal cancer screening and diagnostics market in FY2022.
  • Competitive Strategy: Key players in the global colorectal cancer screening and diagnostics market have been focusing on innovation, differentiation, and strategic collaborations to gain a competitive edge.

EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market

Retrieved on: 
Vendredi, mars 29, 2024
Consumer Electronics, Health, Consumer, Technology, Women, Fitness & Nutrition, Hardware, KRW, Yong In University, Uterus, Exercise, Lifting, Relaxation, Beauty, Pelvis, Rectum, Pregnancy, PMS, Menstruation, Femininity, Nocturia, Uterine prolapse, Pelvic floor, Traction, Urinary incontinence, Elasticity, Premenstrual syndrome, EMS, Multimedia, Dietary supplement

This innovative solution enables people to do Kegel exercises easily by sitting on it, heralding a new era of K-HEALTH CARE.

Key Points: 
  • This innovative solution enables people to do Kegel exercises easily by sitting on it, heralding a new era of K-HEALTH CARE.
  • View the full release here: https://www.businesswire.com/news/home/20240327264174/en/
    The EMS Kegel Trainer BODYDOCTOR FEMFIT has been launched in Japan.
  • (Photo: GENERALNET CORP)
    Derived from combining 'Feminine' and 'Care', the term 'Femcare' encompasses products and services designed to care for women’s bodies and health.
  • Understanding how important it is to strengthen pelvic floor muscles to address these health issues, GENERALNET CORP, a company dedicated to women's health and beauty, launched the EMS Kegel exerciser BODYDOCTOR in January 2019.

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Retrieved on: 
Mardi, mars 26, 2024
Radiation, Prostate cancer, Disease, Incidence, Patient, Rectum, RSS, Prostate, Motion, SBRT, Quality of life, Cyberknife, MBA, Neoplasm, Accuray, Movement, Health, Medical imaging

MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams.

Key Points: 
  • "An extensive number of peer-reviewed scientific manuscripts have been published reporting on CyberKnife prostate SBRT efficacy and tolerability.
  • The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT.
  • Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer2.
  • For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.

Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

Retrieved on: 
Vendredi, mars 15, 2024
Diagnosis, Uncertainty, Histology, Growth, Infertility, Cyst, Disease, University, Pelvis, Endometrioma, Patient, Rectum, Abdomen, Laparoscopy, Endometriosis, Society, Integrin, Woman, SRI, Pain, University of Oxford, FDA, Medical imaging

The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.

Key Points: 
  • The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.
  • Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford added: "Endometriosis is a common disease affecting many millions of women worldwide with pain and infertility.
  • Therefore, a novel imaging tool to assist healthcare professionals in identifying or ruling out the disease is urgently needed."
  • At the Endometriosis CaRe Centre at the University of Oxford our studies focus on identifying novel genetic, diagnostic and therapeutic targets for endometriosis.

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Retrieved on: 
Lundi, mars 4, 2024
TMS, Woman, Diarrhea, FDA, Quality of life, Tenesmus, Food, DIE, Endometriosis, Quality, Constipation, Dyspareunia, Rectum, Prostate, Fatigue, EDAP, Patient, Diagnosis, MRI, Weakness, Pharmaceutical industry

“This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.

Key Points: 
  • “This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.
  • The Focal One system being granted a Breakthrough Device designation underscores the significance of this innovative development for DIE patients.
  • In January 2022, EDAP reported positive results from the Phase 2 Endo-HIFU-1R study (N=60) evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis, and this data was included in EDAP’s submission in consideration for receiving Breakthrough Device designation from the FDA.
  • In February 2024, EDAP announced the completion of enrollment in a Phase 3 study evaluating Focal One HIFU therapy for the treatment of deep infiltrating rectal endometriosis.

NY Cancer Survivor Offers Blueprint for Patient Empowerment

Retrieved on: 
Mercredi, mars 6, 2024
Proton, Shock, Empowerment, Hope, Procurement, Life, Radiation, Proton therapy, Rectum, PSA, Diagnosis, Research, Cancer, Medical imaging

SOMERSET, N.J., March 6, 2024 /PRNewswire/ -- Walter Krysevig, a 77-year-old cancer survivor from Somers, NY, embodies the transformative power of patient empowerment in navigating complex medical decisions.

Key Points: 
  • SOMERSET, N.J., March 6, 2024 /PRNewswire/ -- Walter Krysevig, a 77-year-old cancer survivor from Somers, NY, embodies the transformative power of patient empowerment in navigating complex medical decisions.
  • His proactive approach not only reshaped his treatment journey but also serves as a blueprint for others facing similar challenges.
  • Faced with a diagnosis of Stage 4 prostate cancer, Krysevig refused to accept a passive role in his care.
  • As Krysevig celebrates a major milestone of five years post-diagnosis, his story shows that patient empowerment can lead to positive outcomes.

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Jeudi, février 29, 2024
Large intestine, Ulcerative colitis, Incidence, American Cancer Society, Woman, Crohn's disease, Diet, Colorectal cancer, Smoking, Cancer, ACS, Hereditary nonpolyposis colorectal cancer, Weight loss, Polyp, Colorectal Cancer Alliance, Exercise, Calcium, Meat, Risk, Weakness, Survival rate, Alaska Natives, Vegetable, Rectum, USPSTF, Fatigue, Chronic pain, Death, Black, Locator, Ageing, Dairy

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.

Colorectal cancer is the 2nd deadliest cancer in Canada, let's work together to avoid making it number one

Retrieved on: 
Lundi, février 26, 2024
Large intestine, Incidence, CCC, Woman, Colorectal cancer, Education, Hereditary nonpolyposis colorectal cancer, Learning, Communication, Risk, Health, Rectum, Organization, Disease, Ageing, Cancer

Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.

Key Points: 
  • Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.
  • Despite being preventable and highly treatable when detected early, the reluctance to participate in colorectal cancer screening has hindered early detection efforts.
  • This alarming reality serves as a stark reminder that vigilance and advocacy are paramount in the fight against colorectal cancer.
  • Join Colorectal Cancer Canada in our mission to save lives, break barriers, and promote equitable access to colorectal cancer resources across Canada.

Lancet Digital Health Study Confirms MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Retrieved on: 
Jeudi, février 22, 2024
AI, Colonoscopy, FDA, ADR, Polyp, EYE, CRC, Risk, Rectum, Patient, Adenoma, Mortality, Colorectal cancer, Research, AMR, Cancer, Medical device

HAIFA, Israel, Feb. 22, 2024 /PRNewswire/ -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Key Points: 
  • The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category.
  • The study shows that using MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values.
  • In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
  • "We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research," said Dror Zur, Founder & CEO, MAGENTIQ EYE.